Treatment of canine cutaneous leishmaniasis.
D000038:Abscess / Q000139:chemically induced / Q000662:veterinary; D000818:Animals; D000965:Antimony / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004283:Dog Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D004285:Dogs; D007273:Injections, Intramuscular; D007891:Leishmania / Q000302:isolation & purification; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology / Q000662:veterinary*; D012871:Skin Diseases / Q000139:chemically induced / Q000662:veterinary; D012964:Sodium / Q000008:administration & dosage / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D000965:Antimony; D012964:Sodium